| Autor: |
Sarah Ali Alghamdi, Rha Ismail, Shaza Samargandy |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Saudi Journal for Health Sciences, Vol 12, Iss 2, Pp 165-166 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2278-0521 |
| DOI: |
10.4103/sjhs.sjhs_46_23 |
| Popis: |
Alemtuzumab (ALZ) is a humanized monoclonal antibody licensed for the treatment of relapsing–remitting multiple sclerosis (RRMS). One of its common side effects is autoimmune thyroid disease, most commonly Graves' disease (GD). Here, we present a case of a 39-year-old female that was on ALZ for the treatment of RRMS. After two cycles, she developed GD, which later converted to severe hypothyroidism. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
